Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer

Benzer Materyaller

• A brand new era of cancer immunotherapy: breakthroughs and challenges
  Yazar:: Bai, Ri-Lan, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids
  Yazar:: Sun, Lejia, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment
  Yazar:: Krieger, Tina, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Programmed cell death-1/programmed cell death-ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages
  Yazar:: Jia, Lingling, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer
  Yazar:: Dong, Zhengwei, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)